Pulmonx Corporation (NASDAQ: LUNG) is a Healthcare company (Medical - Devices) with a market capitalization of $119M. The Maz Rating grades it against the other companies in its sector.
Pulmonx Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.73, Pulmonx Corporation trades at 1.4x sales and 3.5x book value. Over the last twelve months it generated about $87M of revenue and a net loss of $43M. It runs a gross margin of 77.4%, an operating margin of -44.4% and a net margin of -47.9%. It shows return on equity of -98.2%, return on invested capital of -43.3% and a free cash flow yield of -21.0%. On the balance sheet: a debt-to-equity ratio of 1.65 and a current ratio of 4.05. Over the past 52 weeks the share price ranged from $1.13 to $3.25, with a beta of 0.28.
Pulmonx Corporation does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 4 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.